CSL LTD SPON.ADR 2CSL LTD SPON.ADR 2CSL LTD SPON.ADR 2

CSL LTD SPON.ADR 2

No trades
See on Supercharts
Market capitalization
‪80.02 B‬EUR
‪2.06 B‬EUR
‪12.08 B‬EUR
Beta (1Y)
0.75

About CSL LTD SPON.ADR 2

CEO
Paul McKenzie
Website
Headquarters
Melbourne
Employees (FY)
‪32 K‬
Founded
1961
ISIN
US12637N2045
FIGI
BBG0074TGM73
CSL Ltd. is a biopharmaceutical company, which engages in the manufacture, marketing, and distribution of biopharmaceutical and allied products. It operates through the following segments: CSL Behring, CSL Seqirus, and CSL Vifor. The CSL Behring segment provides plasma products, gene therapies, and recombinants. The CSL Seqirus segment includes predominantly influenza related products and provides pandemic services to governments. The CSL Vidor segment focuses on the distribution of products in the therapeutic areas of iron deficiency and nephrology. The company was founded on November 2, 1961 and is headquartered in Melbourne, Australia.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬

See all ideas 

Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.